

Store at  
-20C  
#85677**IL-13RA2/CD213a2 (E7U7B) Rabbit mAb**

**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

<b>Applications:</b> W, IP, IHC-Bond, IHC-P, FC-L	<b>Reactivity:</b> H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 55, 65	<b>Source/Isotype:</b> Rabbit IgG	<b>UniProt ID:</b> #Q14627	<b>Entrez-Gene Id:</b> 3598
---	-------------------------	-----------------------------------	----------------------------	--------------------------------------	-------------------------------	--------------------------------

**Product Usage Information****Application**

Western Blotting  
Immunoprecipitation  
IHC Leica Bond  
Immunohistochemistry (Paraffin)  
Flow Cytometry (Live)

**Dilution**

1:1000  
1:50  
1:50 - 1:200  
1:100 - 1:400  
1:50

**Storage**

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

For a carrier free (BSA and azide free) version of this product see product #68588.

**Specificity/Sensitivity**

IL-13RA2/CD213a2 (E7U7B) Rabbit mAb recognizes endogenous levels of total IL-13RA2/CD213a2 protein. This antibody does not cross-react with IL-13RA1 protein.

**Source / Purification**

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human IL-13RA2/CD213a2 protein.

**Background**

Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

IL-13 receptor alpha-2 (IL-13RA2/CD213a2) is a type-I monomeric transmembrane glycoprotein and component of the IL-4/IL-13 receptor system. Research studies have shown that IL-13RA2 controls IL-13 signaling by serving as a high affinity decoy receptor for IL-13, but not IL-4, in a variety of cellular contexts (4,5). Some studies, however, have suggested that signaling through IL-13RA2 expressed on immunosuppressive myeloid cells facilitates tumor immune evasion through the production of TGF-β (6,7).

IL-13RA2 displays a highly restricted expression pattern in normal human tissues, which positions this receptor as a potentially novel therapeutic target for multiple types of solid tumors (8-10). Indeed, research studies have shown that IL-13RA2 is highly over expressed in glioblastomas (11), which has prompted investigation of different IL-13RA2-directed immunotherapies to treat this cancer (12-14).

**Background References**

1. Caballero, O.L. and Chen, Y.T. (2009) *Cancer Sci* 100, 2014-21.
2. De Smet, C. et al. (1999) *Mol Cell Biol* 19, 7327-35.
3. Gjerstorff, M.F. et al. (2015) *Oncotarget* 6, 15772-87.
4. Yoshikawa, M. et al. (2003) *Biochem Biophys Res Commun* 312, 1248-55.
5. Bernard, J. et al. (2001) *Lab Invest* 81, 1223-31.
6. Fichtner-Feigl, S. et al. (2006) *Nat Med* 12, 99-106.
7. Fichtner-Feigl, S. et al. (2008) *Cancer Res* 68, 3467-75.
8. Debinski, W. and Gibo, D.M. (2000) *Mol Med* 6, 440-9.
9. Taguchi, A. et al. (2014) *Cancer Res* 74, 4694-705.
10. Beard, R.E. et al. (2013) *Clin Cancer Res* 19, 4941-50.
11. Jarboe, J.S. et al. (2007) *Cancer Res* 67, 7983-6.
12. Brown, C.E. et al. (2015) *Clin Cancer Res* 21, 4062-72.
13. Brown, C.E. et al. (2012) *Clin Cancer Res* 18, 2199-209.
14. Mintz, A. et al. (2008) *Cancer Biother Radiopharm* 23, 581-9.

<b>Species Reactivity</b>	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
<b>Western Blot Buffer</b>	<b>IMPORTANT:</b> For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
<b>Applications Key</b>	<b>W:</b> Western Blotting <b>IP:</b> Immunoprecipitation <b>IHC-Bond:</b> IHC Leica Bond <b>IHC-P:</b> Immunohistochemistry (Paraffin) <b>FC-L:</b> Flow Cytometry (Live)
<b>Cross-Reactivity Key</b>	<b>H:</b> Human
<b>Trademarks and Patents</b>	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. Alexa Fluor is a registered trademark of Life Technologies Corporation. All other trademarks are the property of their respective owners. Visit <a href="http://cellsignal.com/trademarks">cellsignal.com/trademarks</a> for more information.
<b>Limited Uses</b>	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.  Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.